American Capital Advisory’s Avidity Biosciences RNAM Stock Holding History

American Capital Advisory’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$73	–	1201
2025 Q4	$73	Hold	1	–	–	﹤0.01%	1034
2025 Q3	$44	Buy	+1	New	+$40	﹤0.01%	994
2025 Q2	–	Sell	-8	Closed	-$237	–	974
2025 Q1	$237	Buy	+8	New	+$249	﹤0.01%	697

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

American Capital Advisory's RNAM Position: Q1 2026 in Review

American Capital Advisory sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1 share — an estimated $73 sold.

American Capital Advisory first reported a position in RNAM in Q1 2025 and held it in 3 quarters. The position peaked at $237 in Q1 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

American Capital Advisory reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
American Capital Advisory sold 1 Avidity Biosciences share in Q1 2026, an estimated $73.
American Capital Advisory first reported a position in Avidity Biosciences in Q1 2025 and held it in 3 quarters.
American Capital Advisory's Avidity Biosciences position peaked at $237 in Q1 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on American Capital Advisory's 13F filing for Q1 2026, filed 29 Apr 2026.